| abstract |
The invention provides the use of a chemokine receptor CXCR5, which utilizes the tumor-targeting properties of CXCR5 to transform the CXCR receptor to prepare a chimeric antigen receptor to obtain an anti-EGFR chimeric antigen receptor with enhanced chemotaxis ability T cells, which can guide the migration of chimeric antigen receptor T cells to tumors, have excellent ability to enhance the chemotaxis of CAR-T cells, specifically target EGFR-positive tumor cells, and solve the problem of existing CAR-T therapy entities. It has a broad application prospect and huge market value. |